MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)

被引：0
|
作者：
Kull, M. [1 ]
Grosicki, S. [2 ]
Yeh, S. -P. [3 ]
Huang, J. S. Y. [4 ]
Byun, J. M. [5 ]
DiRienzo, C. [6 ]
Viqueira, A. [7 ]
机构：
[1] Univ Hosp Ulm, Dept Hematol, Ulm, Germany
[2] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland
[3] China Med Univ Hosp, Taichung, Taiwan
[4] Taiwan Univ Hosp, Taipei, Taiwan
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Pfizer Inc, New York, NY USA
[7] Pfizer SLU, Madrid, Spain
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1105
引用
收藏
页码：314 / 314
页数：1
相关论文
共 50 条
  • [21] Daratumumab plus Bortezomib/Lenalidomide/ Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
    Usmani, Saad Z.
    Facon, Thierry
    Hungria, Vania
    Bahlis, Nizar J.
    Venner, Christopher P.
    Braunstein, Marc
    Pour, Ludek
    Marti, Josep
    Basu, Supratik
    Cohen, Yael C.
    Matsumoto, Morio
    Suzuki, Kenshi
    Hulin, Cyrille
    Grosicki, Sebastian
    Legiec, Wojciech
    Beksac, Meral
    Maiolino, Angelo
    Liu, Weiping
    Wang, Jianping
    Krevvata, Maria
    Lopez-Masi, Lorena
    Carey, Jodi
    Rowe, Melissa
    Carson, Robin
    Zweegman, Sonja
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S288 - S289
  • [22] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
    Kubo, Kohmei
    Hori, Mitsuo
    Ohta, Kensuke
    Handa, Hiroshi
    Hatake, Kiyohiko
    Matsumoto, Morio
    Hagiwara, Shotaro
    Ohashi, Kazuteru
    Nakaseko, Chiaki
    Suzuki, Kenshi
    Ito, Shigeki
    Kinoshita, Gen
    Shelat, Suresh G.
    Miyoshi, Masafumi
    Takezako, Naoki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 65 - 74
  • [23] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
    Kohmei Kubo
    Mitsuo Hori
    Kensuke Ohta
    Hiroshi Handa
    Kiyohiko Hatake
    Morio Matsumoto
    Shotaro Hagiwara
    Kazuteru Ohashi
    Chiaki Nakaseko
    Kenshi Suzuki
    Shigeki Ito
    Gen Kinoshita
    Suresh G. Shelat
    Masafumi Miyoshi
    Naoki Takezako
    International Journal of Hematology, 2020, 111 : 65 - 74
  • [24] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah A.
    Anderson, Larry D., Jr.
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Bartlett, J. Blake
    Vermeulen, Jessica
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter
    BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [25] Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience
    Moustafa, Muhamad Alhaj
    Parrondo, Ricardo
    Abdulazeez, Mays F.
    Roy, Vivek
    Sher, Taimur
    Alegria, Victoria R.
    Warsame, Rahma M.
    Larsen, Jeremy
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Kapoor, Prashant
    Fonseca, Rafael
    Buadi, Francis K.
    Dingli, David
    Hayman, Suzanne R.
    Reeder, Craig B.
    Agrawal, Arshi
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    BLOOD, 2020, 136
  • [26] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Ajay K. Nooka
    Jonathan L. Kaufman
    Cesar Rodriguez
    Andrzej Jakubowiak
    Yvonne Efebera
    Brandi Reeves
    Tanya Wildes
    Sarah A. Holstein
    Larry D. Anderson
    Ashraf Badros
    Leyla Shune
    Ajai Chari
    Huiling Pei
    Annelore Cortoos
    Sharmila Patel
    J. Blake Bartlett
    Jessica Vermeulen
    Thomas S. Lin
    Paul G. Richardson
    Peter Voorhees
    Blood Cancer Journal, 12
  • [27] MagnetisMM-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma
    Kortuem, M.
    Manteca, Mateos M. V.
    Grosicki, S.
    Kim, K.
    Negre, E.
    Vandendries, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 182 - 182
  • [28] Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
    Gay, Francesca
    Musto, Pellegrino
    Rota-Scalabrini, Delia
    Bertamini, Luca
    Belotti, Angelo
    Galli, Monica
    Offidani, Massimo
    Zamagni, Elena
    Ledda, Antonio
    Grasso, Mariella
    Ballanti, Stelvio
    Spadano, Antonio
    Cea, Michele
    Patriarca, Francesca
    D'Agostino, Mattia
    Capra, Andrea
    Giuliani, Nicola
    de Fabritiis, Paolo
    Aquino, Sara
    Palmas, Angelo
    Gamberi, Barbara
    Zambello, Renato
    Petrucci, Maria Teresa
    Corradini, Paolo
    Cavo, Michele
    Boccadoro, Mario
    LANCET ONCOLOGY, 2021, 22 (12) : 1705 - 1720
  • [29] Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
    Narsipur, Nihal
    Bulla, Sabrina
    Yoo, Connie
    Do, Brenda
    Tran, Kyle
    Gu, Dian
    Zhong, Lixian
    Wilson, Leslie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (12) : 1691 - 1702
  • [30] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
    Nizar J. Bahlis
    Meletios A. Dimopoulos
    Darrell J. White
    Lotfi Benboubker
    Gordon Cook
    Merav Leiba
    P. Joy Ho
    Kihyun Kim
    Naoki Takezako
    Philippe Moreau
    Jonathan L. Kaufman
    Maria Krevvata
    Christopher Chiu
    Xiang Qin
    Linda Okonkwo
    Sonali Trivedi
    Jon Ukropec
    Ming Qi
    Jesus San-Miguel
    Leukemia, 2020, 34 : 1875 - 1884
12345